Plague Pipeline

Same vector platform as the Oxford COVID-19 vaccine

A replication-deficient chimpanzee adenovirus, ChAdOx1, carrying genes for F1 and V. It is the same vector family as Oxford’s COVID-19 vaccine. This trial is not AstraZeneca’s: the sponsor is the University of Oxford and the funder is Innovate UK. Phase 1 in about 40 healthy adults, protocol OVG 2019/05, registry ISRCTN41077863, opened in July 2021. One or two intramuscular doses. No marketing authorisation.

Stage chart

Preclinical

Phase 1

Phase 2

Phase 3

Licensed

Phase 1 · n=40. Phase 3 is empty here, as it is for every programme in the set.

Years on the record

A mark at 2021. Labelled “Jul 2021” on the briefing. Not a forecast.

Analyst card

Challenge: Phase 1 safety and immunogenicity in about 40 adults. No pathogen challenge.
F1-negative strains: Not reported. The vector carries F1 and V.
Adjuvant: None added. ChAdOx1 is the delivery.
Route: One or two intramuscular doses of 5 × 10¹⁰ virus particles.
Stability: Formulation and cold-chain requirement are not stated.
Time to protection: Not reported. No time-to-protection figure is in the briefing.
Other threats: Plague only. This is not the AstraZeneca COVID vaccine.
Survival figure: No survival figure.
Animal Rule: UK Phase 1. Not an FDA Animal Rule file.

Pipeline record

Vector: Replication-deficient chimpanzee adenovirus ChAdOx1, carrying F1 and V. Same vector family as Oxford’s COVID-19 vaccine. This product is not AstraZeneca’s.
Dose: 5 × 10¹⁰ virus particles, one or two intramuscular injections.
Registries: ISRCTN41077863. EU CTIS 2020-000710-15. IRAS 279095. Protocol OVG 2019/05.
People: About 40 healthy adults, 18 to 55. Opened July 2021.
Sponsor: University of Oxford. Funder: Innovate UK. No marketing authorisation.

Registries

ISRCTN41077863 · ISRCTN · ChAdOx1 PlaguePhase 1. University of Oxford. Innovate UK. Protocol OVG 2019/05. EU CTIS 2020-000710-15. Opened July 2021. About 40 adults aged 18 to 55. One or two doses of 5 × 10¹⁰ virus particles.

News

Checking today’s headlines.

Latest intel

Checking Europe PMC.

PubMed

Checking today’s index.

Platform: Viral vector
A virus that does not cause plague carries genes for plague antigens. One candidate uses ChAdOx1, the same chimpanzee adenovirus as Oxford's COVID-19 vaccine. Another is an adenovirus construct still in primates.
Who is paying: UK — Innovate UK (UKRI), Oxford Vaccine Group
Country: United Kingdom
What was tested: Human · Phase 1
Stage: Phase 1 · n=40
Date: Jul 2021
Antigens named: F1V / LcrV